name	nt_name	aa_name	multi_aa_name	multiaa_mutation_split_names	start	vcf_gene	chrom_region	mutation_type	dp	obs_sample_size	variant_pop_size	ps_filter	ps_exc	mat_pep_id	mat_pep_desc	mat_pep_acc	ro	ao_by_var_seq	ao	variant_seq	reference_seq	function_category	citation	citation_url	comb_mutation	function_description	heterozygosity	viral_lineages	clade_defining_status	status	voi_designation_date	voc_designation_date	vum_designation_date
c.C-25T	c.C-25T				241	orf1ab	5' UTR		742	742	742						0	T=742	742	T	C						False	B.1.351.5, B.1.351.2, B.1.351, B.1.351.3	B.1.351.5=True, B.1.351.3=True, B.1.351.2=True, B.1.351=True	VOC		18-Dec-2020	
c.C29754T	c.C*4370T				29754	intergenic	Stem-loop,3' UTR		638	670	742						457	T=181	181	T	C						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
c.G-24T	c.G-24T				27870	ORF8	intergenic		670	670	742						564	T=106	106	T	G						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
c.G-92T	c.G-92T				174	orf1ab	5' UTR		742	742	742						0	T=742	742	T	G						False	B.1.351.5, B.1.351.2, B.1.351, B.1.351.3	B.1.351.5=True, B.1.351.3=True, B.1.351.2=True, B.1.351=True	VOC		18-Dec-2020	
p.3676del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', 'F3677del'	11287	orf1ab	ORF1ab		748	1472	742			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=748	748	G	GTCTGGTTTT						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A1316A	c.T3948C	p.A1316A			4213	orf1ab	ORF1ab	SILENT	670	670	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	596	C=74	74	C	T						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.A243del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'L242del'	22280	S	S		648	736	742						1	A=639	639	A	ACTTTACTTG	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A243del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'L242del'	22280	S	S		648	736	742						1	A=639	639	A	ACTTTACTTG	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A243del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'L242del'	22280	S	S		648	736	742						1	A=639	639	A	ACTTTACTTG	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A27S	c.G79T	p.A27S			21641	S	S	MISSENSE	670	670	742						596	T=74	74	T	G						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.A3456V	c.C10367T	p.A3456V			10632	orf1ab	ORF1ab	MISSENSE	12	12	742			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=12	12	T	C						False	B.1.351.2	B.1.351.2=True	VOC		18-Dec-2020	
p.A3625V	c.C10874T	p.A3625V			11139	orf1ab	ORF1ab	MISSENSE	12	12	742			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	4	T=8	8	T	C						False	B.1.351.2	B.1.351.2=False	VOC		18-Dec-2020	
p.A3730A	c.C11190T	p.A3730A			11455	orf1ab	ORF1ab	SILENT	24	24	742			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	6	T=18	18	T	C						False	B.1.351.2	B.1.351.2=False	VOC		18-Dec-2020	
p.A6296V	c.C18887T	p.A6296V			19151	orf1ab	ORF1ab	MISSENSE	12	12	742			3'-to-5' exonuclease	nsp14A2_ExoN and nsp14B_NMT, produced by pp1ab only	YP_009725309.1	10	T=2	2	T	C						False	B.1.351.2	B.1.351.2=False	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	reinfection	Staub et al. (2021)	https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423	'D80A', 'D215G', 'K417N', 'N501Y', 'E484K'	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	reinfection	Yinda et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1	'D80A', 'D215G', 'K417N', 'N501Y', 'E484K'	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	symptom prevalence	Munster et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1	'D80A', 'D215G', 'K417N', 'N501Y', 'E484K'	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy			'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y'	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.A701V	c.C2102T	p.A701V			23664	S	S	MISSENSE	736	736	742						0	T=736	736	T	C	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.33 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	homoplasy	Borges et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.19.444774v1		In experimental models of SARS-CoV-2 mutational evolution (without immune pressure), this mutation in the N terminal domain appears convergent. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	reinfection	Staub et al. (2021)	https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423	'D80A', 'K417N', 'A701V', 'N501Y', 'E484K'	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	reinfection	Yinda et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1	'D80A', 'K417N', 'A701V', 'N501Y', 'E484K'	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	symptom prevalence	Munster et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1	'D80A', 'K417N', 'A701V', 'N501Y', 'E484K'	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy			'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'D80A', 'K417N', 'E484K', 'N501Y', 'A701V'	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D215G	c.A644G	p.D215G			22206	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.98 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D3450D	c.C10350T	p.D3450D			10615	orf1ab	ORF1ab	SILENT	54	54	742			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=54	54	T	C						False	B.1.351.3	B.1.351.3=True	VOC		18-Dec-2020	
p.D4769D	c.C14307T	p.D4769D			14571	orf1ab	ORF1ab	SILENT	54	54	742			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	32	T=22	22	T	C						False	B.1.351.3	B.1.351.3=False	VOC		18-Dec-2020	
p.D5902D	c.T17706C	p.D5902D			17970	orf1ab	ORF1ab	SILENT	670	670	742			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	596	C=74	74	C	T						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed essentially no change in binding (KD) relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D215G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.19x increase in binding (KD) relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D80A'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Li et al. (2020)	https://doi.org/10.1016/j.cell.2020.07.012		In four cell lines (including 293T-hACE2 cells), this mutation combination increases infectivity vs D614G alone	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'N501Y'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.11x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D215G'	2.29x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D80A'	2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F'	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'K417N', 'E484K', 'N501Y'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'N501Y'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	immunosuppression variant emergence	Landis et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.08.21256775v1		Studying 94 COVID-19 extended infection cases with genomics April 1 to October 17, 2020, one case developed 23 mutations in a 19 day period, including this combination in Spike.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5		The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: results (only one nasal  swab from different previously infected vacinee neutralizing at weeks 3 and 6 against B.1.1.7 and D614G) suggest that vaccinees probably  do not elicit an early humoral response detectable at mucosal surfaces even though sera neutralization was observed. They strengthen the hypothesis that some vaccines may not protect against  viral acquisition and infection of the oral–nasal region, but may prevent severe disease associated with viral dissemination in the lower respiratory tract. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Barrett et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.24.428007v1		Circulating variant shown in vitro to not have major defects or enhancement of cell surface protein trafficking (i.e. Spike cleavage or fusion required for cell entry)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Daniloski et al. (2021)	https://doi.org/10.7554/elife.65365		The increased transduction with Spike D614G ranged from 1.3- to 2.4-fold in Caco-2 and Calu-3 cells expressing  endogenous ACE2 and from 1.5- to 7.7-fold in A549ACE2 and Huh7.5ACE2 overexpressing ACE2.  Although there is minimal difference in ACE2 receptor binding between the D614 and G614 Spike variants,  the G614 variant is more resistant to proteolytic cleavage, suggesting a possible mechanism for the increased transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'N501Y'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		No change in infectivity (24h) relative to D614G alone in Caco-2 cells, Vero or Calu-3.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633		~4x more efficient S2 domain cleavage compared to wild type in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'N501Y'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'K417N'	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'K417N', 'N501Y'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	748	1472	742						0	G=748	748	G	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Ozono et al. (2020)	https://www.nature.com/articles/s41467-021-21118-2		Among S variants tested, the D614G mutant shows the highest cell entry (~3.5x wild type), as supported by  structural and binding analyses. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	trafficking	Zhang et l. (2020)	https://www.nature.com/articles/s41467-020-19808-4		We report here pseudoviruses carrying SG614 enter ACE2-expressing cells more efficiently than wild type (~9-fold).  This increased entry correlates with less S1-domain shedding and higher S-protein incorporation into the virion.  D614G does not alter S-protein binding to ACE2 or neutralization sensitivity of pseudoviruses. Thus, D614G may  increase infectivity by assembling more functional S protein into the virion.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'K417N', 'E484K', 'N501Y'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'K417N', 'E484K', 'N501Y'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy			'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013		Pseudotyped D614G virus has reduced neutralization activity vs wild type: 1.2x (37 sera Pfizer median 9  days post 2nd dose, 37 sera Moderna median 18 days post 2nd dose). This was NOT significant by ANOVA.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		Using a lentivirus virus pseudotyped with D614G Spike, sera from vaccinated individuals who received the second dose (9–11 days post-second dose of Pfizer) exhibited a robust  neutralizing potential, with a mean NT50 value of 99,000. This was an average of a 2-fold increase, relative to sera drawn from the  individuals who received one dose of vaccination—mean NT50 dilution of 51,300. Importantly, a 6-fold increase in mean NT50 dilution was  obtained when sera from the first vaccination dose was compared to convalescent sera from cohort with severe disease (NT50 51,000 vs 8,700)  21 to 63 days post-onset. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K'	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K', 'N501Y'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'K417N', 'E484K', 'N501Y'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'A701V'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'E484K'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'A701V'	1.19x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.1x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D215G'	1.79x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.3x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D80A'	1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'E484K'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'K417N'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'L18F'	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'N501Y'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	viral load	Plante et al. (2020)	https://www.nature.com/articles/s41586-020-2895-3		Hamsters infected with SARS-CoV-2 expressing spike(D614G) (G614 virus) produced higher infectious titres in nasal washes and the trachea, but not in the lungs,  supporting clinical evidence showing that the mutation enhances viral loads in the upper respiratory tract of COVID-19 patients and may increase transmission.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 2.5 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	virion structure	Weissman et al. (2020)	https://www.medrxiv.org/content/10.1101/2020.07.22.20159905v2		"Negative stain EM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	virion structure	Yurkovetskiy et al. (2020)	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7492024/		"CryoEM shows increased proportion of ""one-up"" trimer conformation of Spike proteins on the surface of virions, where the up  conformation is presumed to be more likely to bind ACE2."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D614G	c.A1841G	p.D614G			23403	S	S	MISSENSE	736	736	742						0	G=736	736	G	A	virion structure	Zhang et al. (2020)	https://www.nature.com/articles/s41467-020-19808-4		Based on pseudotyped virus experiments, D614G may increase infectivity by assembling more functional S protein into the virion.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant combination showed no change relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	CD8 plus T cell response	Redd et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.11.21251585v1		One individual of 30 in the study, with HLA supertype HLA*A24:02, had a linear epitope that overlaps this variant of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Abolishes neutralizing activity of N-terminal-domain-directed mAb 4-19.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.11x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	reinfection	Staub et al. (2021)	https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423	'D215G', 'K417N', 'A701V', 'N501Y', 'E484K'	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	reinfection	Yinda et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1	'D215G', 'K417N', 'A701V', 'N501Y', 'E484K'	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	symptom prevalence	Munster et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1	'D215G', 'K417N', 'A701V', 'N501Y', 'E484K'	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy			'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'D215G', 'K417N', 'E484K', 'N501Y', 'A701V'	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D215G', 'K417N', 'E484K', 'N501Y', 'A701V', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.64x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.35x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	virion structure	Cai et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1	'L18F', 'L242del'	The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.D80A	c.A239C	p.D80A			21801	S	S	MISSENSE	735	736	742						0	C=735	735	C	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated that there is no free energy change (ddG) for this variant (i.e. same stability as wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'K417N', 'N501Y'	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'N501Y'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	This variant appears twice in the experiments, with slightly different affinities (both ~1.2x decrease in binding relative to D614G)  using flow cytometry and ACE2 ectodomains-Fc portion IgG complex.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.06 fold	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported moderate increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected variants in an in vitro evolution experiment for ACE2 binding.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Analyzing responses to the E484K mutation seen in B.1.351 and P.1 variants, we noted that it did  not fall in a region predicted to bind the HLAII alleles tested (table S4). The mutation appeared  to have no substantial or differential impact on T cell responses.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w		Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384 and S2H58.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2N28, S2X615, S2N12, S2X192, S2H7, S2X16, S2X58, S2H70, S2X613, S2D19, S2N22, S2D32, S2H58, S2M11, S2D106, S2X30.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Gaebler et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.03.367391v2		Ablates binding by class 2 mAbs such as C144 that directly interfere with ACE2 binding,  but clonal somatic mutations of memory B cells at 6.2 months (evolving humoral immune response)  show pronounced increase in binding to the variant. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'N501Y', 'D614G'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Li et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.19.440481v1		Monoclonal antibodies 13G9 and 58G6 maintain fairly high neutralization potency, compared to others interfacing with E484K.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Liu et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Mutant screen in neutralization assay with a broad range of monoclonal antibodies shows high resistence to 4 antibodies,  and broad low level resistence against much of the rest of the panel.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Rappazzo et al. (2021)	https://science.sciencemag.org/content/371/6531/823		Massive reduction in binding efficiency vs wild type for mAb LY-CoV555.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		Complete loss of binding in ELISA by the variant against monoclonal antibody VH-Fc ab8	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	'K417N', 'N501Y'	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates neutralization by RBD-directed mAbs 4-20, 2-4, 2-43, 2-30, 2-15, LY-Cov555, C121. Pseudotyped virus model impairs neutralization by RBD-directed mAb COV2-2196 (somewhat more than fully pseudotyped B.1.351 or live virus)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Resistent to all seven class 2 (Spike 'up' or 'down' conformation, RBD targeting) antibodies tested, with 10-fold  or greater reduction in neutralization (plus notable reudction in two unclassfied mAbs).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1	'K417N', 'N501Y'	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.42x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1		Average ~5-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'K417N', 'N501Y', 'D614G'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Andreano et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.12.28.424451		This mutation occurred in 100% of sequenced virions after 12 passages and led to a 4-fold decrease in convalescent plasma neutralization activity	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'N501Y', 'D614G'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'K417N'	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2020.11.06.372037v2		Remarkably, several of the E484 escape mutants were resistant to neutralization at the highest concentration (1:80 initial dilution) of all 4 convalescent sera tested (triplicate experiments). Against a wider panel of 16 convalescent plasma (no replicates), all but one show major resistance.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Schmidt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.06.455491v1		Escape mutant found after in passage in plasma pool of 26 convalescents mean 1.5 post symptom onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		The only mutation in the B.1.351 lineage that appears to contribute to neutralization reduction (~1.7x across 10 convalescent sera from April 2020 infectees)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.5-fold resistant to neutralization by convalescent sera compared to wild type - a finding that was similar to that of the 3-fold resistance of the South Africa B.1.351 variant using the same assay. The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618. [details on the convalescent patient sera collection are not abundantly clear in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the E484K mutation alone showed a mean 19.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1	'K417N', 'N501Y'	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		The neutralizing activity of 15/20 convalescent sera was significantly lower against this pseudotyped virus model	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	convalescent plasma escape	Zhou et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436620v1		"Subtype of the B.1.526 ""New York"" lineage, lentivirus pseudotyped with this mutation combination in showed 3.3x reduction in  IC50 serum dilution concentration for 6 convalescent sera."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	monoclonal antibody serial passage escape	Barnes et al. (2020)	https://www.nature.com/articles/s41586-020-2852-1_reference.pdf?origin		The engineered mutation cause 10-fold or more increase in the disassociation constant with many monoclonal antibodies (C144/C002/C121/C104/C110).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	monoclonal antibody serial passage escape	Baum et al. (2020)	http://dx.doi.org/10.1126/science.abd0831		Escape variant 100% appearance in 2 passages against Regeneron monoclonal antibody REGN10989 @ 50ug/mL (99% after one passage)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	monoclonal antibody serial passage escape	Greaney et al. (2020)	https://doi.org/10.1016/j.chom.2020.11.007		Mildly effective mutant against this position in the RBD for highly neutralizing COV2-2479 monoclonal antibody Effective mutant against this position in the RBD for highly neutralizing COV2-2050 monoclonal antibody	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV555 (antibody that forms the basis for Eli Lilly's bamlanivimab)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		Class 2 antibodies C627, C602, C671, C643, and class 2/3 antibody C603 selected for the emergence of the E484K mutation in vitro.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	monoclonal antibody serial passage escape	Weisblum et al. (2020)	https://www.biorxiv.org/content/10.1101/2020.07.21.214759v1.full.pdf		Strong positive selection (up to 50% of supernatant sequences) after C121 monoclonal antibody assay, decreasing in subsequent passages Strong positive selection (up to 44% of supernatant sequences) after after one round of C144 monoclonal antibody passage, then waning on subsequent passages	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Bamlanivimab (LY-CoV555) lost ~16x binding against this isolated mutation. Casirivimab lost ~16x binding against this isolated mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417N'	Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	reinfection	Staub et al. (2021)	https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423	'D80A', 'D215G', 'K417N', 'A701V', 'N501Y'	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	reinfection	Yinda et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1	'D80A', 'D215G', 'K417N', 'A701V', 'N501Y'	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	symptom prevalence	Munster et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1	'D80A', 'D215G', 'K417N', 'A701V', 'N501Y'	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Ferriera et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		This variant alone shows a ~5x decrease in cell entry efficiency (RLU measurement in 293T cells) compared to D614G. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'N501Y', 'D614G'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'N501Y', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y', 'D614G'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing no change in infection rate amongst the cells.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'K417N', 'N501Y', 'D614G'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'K417N', 'N501Y', 'D614G'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy			'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'D80A', 'D215G', 'K417N', 'N501Y', 'A701V'	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'K417N', 'N501Y'	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w	'N501Y'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Ferreira et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.08.443253v1		Nine stored sera from Pfizer BNT162b2 vaccinees were tested against a range of spike mutation bearing PV. E484K conferred a ten-fold reduction in neutralisation by vaccine sera.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1		E484K pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. A cohort of 12 Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed a mean 2.8x decrease in neutralization effiacacy.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Jangra et al. (2021)	https://doi.org/10.1016/S2666-5247(21		Human sera from 5 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) neutralized this variant 3.4x less relative to reference  USA-WA1/2020 strain. 8 convalescent plasma with weak IgG ELISA titre neutralized this variant 2.4x less relative to reference  USA-WA1/2020 strain. One plasma failed to neutralize at all. 11 convalescent plasma with moderate IgG ELISA titre neutralized this variant 4.2x less relative to reference  USA-WA1/2020 strain.  11 convalescent plasma with high IgG ELISA titre neutralized this variant 2.6x less relative to reference  USA-WA1/2020 strain. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'N501Y', 'D614G'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'K417N'	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'K417N', 'N501Y', 'D614G'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Solfrosi et al. (2021)	https://doi.org/10.1084/jem.20202756		Neutralizing antibody titers of non-human primate sera after one or two doses of Ad26.COV2.S (Jannsen vaccine)  against the variants containing the E484K substitution in the RBD were present but reduced  (fold reduction between 3.35–7.78, 95% confidence interval all above twofold difference, one-sample t test). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'N501Y', 'A701V', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D614G'	Pseudotyped viruses for B.1.618 was 2.7-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type - a finding that was similar to that of the 3.4-fold resistance of the South Africa B.1.351 variant using the same assay. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 3-fold resistant (vs. 2.2-fold for B.1.351). The resistance of B.1.618 was caused by the E484K mutation, based on results from viruses pseudotyped for individual variants within B.1.618.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  ELISA tests show 10x reduced efficacy of a majority of isolated antibodies, but only a modest decrease for vaccine plasma overall.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	'K417N', 'N501Y'	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Wu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	'K417N', 'N501Y'	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Xie et al. (2021)	https://www.nature.com/articles/s41591-021-01270-4	'N501Y'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'D215G', 'L242del', 'K417N', 'N501Y', 'D614G', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.06x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	viral load	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	'K417N', 'N501Y'	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	viral load	Teyssou et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1	'K417N', 'N501Y'	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.E484K	c.G1450A	p.E484K			23012	S	S	MISSENSE	732	736	742						0	A=732	732	A	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.6 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.F120F	c.C360T	p.F120F			28253	ORF8	ORF8	SILENT	65	66	742	mask	highly_homoplasic				0	T=65	65	T	C						False	B.1.351.2, B.1.351.3	B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.F28F	c.C84T	p.F28F			26606	M	M	SILENT	12	12	742						10	T=2	2	T	C						False	B.1.351.2	B.1.351.2=False	VOC		18-Dec-2020	
p.F3677del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'S3675del', '3676del'	11287	orf1ab	ORF1ab		736	736	742			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=736	736	G	GTCTGGTTTT						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.F924F	c.C2772T	p.F924F			3037	orf1ab	ORF1ab	SILENT	736	736	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=736	736	T	C						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.G133G	c.C399T	p.G133G			664	orf1ab	ORF1ab	SILENT	6	6	742			leader protein	nsp1, produced by both pp1a and pp1ab	YP_009725297.1	1	T=5	5	T	C						False	B.1.351.5	B.1.351.5=True	VOC		18-Dec-2020	
p.G254X	c.G760T	p.G254X			26152	ORF3a	ORF3a	NONSENSE	670	670	742						288	T=382	382	T	G						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.G3849G	c.C11547A	p.G3849G			11812	orf1ab	ORF1ab	SILENT	1340	1340	742			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	1192	A=148	148	A	C						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.I121L	c.CA360_361TC	p.I121L			28253	ORF8	ORF8		664	670	742						0	TC=103, TA=561	103,561	TC,TA	CA						False	B.1.351	B.1.351=True	VOC		18-Dec-2020	
p.I5475V	c.A16423G	p.I5475V			16687	orf1ab	ORF1ab	MISSENSE	54	54	742			helicase	nsp13_ZBD, nsp13_TB, and nsp_HEL1core, zinc-binding domain (ZD), NTPase/helicase domain (HEL), RNA 5'-triphosphatase, produced by pp1ab only	YP_009725308.1	0	G=54	54	G	A						False	B.1.351.3	B.1.351.3=True	VOC		18-Dec-2020	
p.I666I	c.T1998C	p.I666I			23560	S	S	SILENT	12	12	742						10	C=2	2	C	T						False	B.1.351.2	B.1.351.2=False	VOC		18-Dec-2020	
p.K1655N	c.G4965T	p.K1655N			5230	orf1ab	ORF1ab	MISSENSE	736	736	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=736	736	T	G						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K3353R	c.A10058G	p.K3353R			10323	orf1ab	ORF1ab	MISSENSE	736	736	742			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	G=736	736	G	A						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The K417N mutation decreased the affinity ~4 fold, mainly by decreasing the k(on) but also by increasing the k(off) as measured by surface plasmon resonance.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'E484K', 'N501Y'	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.5x decrease in binding (KD) relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 3-fold decrease in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K', 'N501Y'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'E484K', 'N501Y', 'D614G'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1		>20% (ELISA significance threshold) drop in antibody binding (ELISA) by this variant against IgG1 monoclonal antibody ab1.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	'E484K', 'N501Y'	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		5 antibodies tested were less potent against K417N by ten-fold or more (class 1 mAbs)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Pseudotyped virus model ablates binding by RBD-directed mAbs CB6 and 910-30 (targeting the inner side of the RBD). Pseudotyped virus model impairs binding by RBD-directed mAbs 4-20 and REGN10933.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1	'E484K', 'N501Y'	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	2.16x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'E484K', 'N501Y', 'D614G'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		In 19 convalescent human sera ~1mo post infection, Two-tailed Wilcoxon matched-pairs signed-rank test shows mild resistence P	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K', 'N501Y'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'E484K', 'N501Y', 'D614G'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'E484K'	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'E484K', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1	'E484K', 'N501Y'	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	gene expression increase	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, Spike gene expression increased 0.1 fold	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	monoclonal antibody serial passage escape	Starr et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.17.431683v1		Escape mutation against monoclonal antibody LY-CoV016	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C682, and to a lesser extent C614 and C660	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~6x binding against this isolated mutation. Estesevimab lost ~100x binding against this isolated mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K'	Bamlanivimab (LY-CoV555) lost ~32x binding against this double mutation. COR-101 lost ~160x binding against this double mutation. Casirivimab lost ~16x binding against this double mutation. Estesevimab lost ~32x binding against this double mutation. Regdanvimab lost ~4x binding against this double mutation. Tixagevimab lost ~12x binding against this double mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'N501Y'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	reinfection	Staub et al. (2021)	https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423	'D80A', 'D215G', 'A701V', 'N501Y', 'E484K'	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	reinfection	Yinda et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1	'D80A', 'D215G', 'A701V', 'N501Y', 'E484K'	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	symptom prevalence	Munster et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1	'D80A', 'D215G', 'A701V', 'N501Y', 'E484K'	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'E484K', 'N501Y', 'D614G'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	~2x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	Approximately as infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of the individual variants).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y', 'D614G'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  mutation does not contributing to cell entry fitness.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'E484K', 'N501Y', 'D614G'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'E484K', 'N501Y', 'D614G'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy			'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'D80A', 'D215G', 'E484K', 'N501Y', 'A701V'	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'E484K', 'N501Y'	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed only minor in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	This variant showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'N501Y', 'D614G'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'N501Y', 'E484K'	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'E484K', 'N501Y', 'D614G'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'E484K', 'N501Y', 'A701V', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	'E484K', 'N501Y'	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Wu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	'E484K', 'N501Y'	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'D215G', 'L242del', 'E484K', 'N501Y', 'D614G', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.76x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.75x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	viral load	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	'E484K', 'N501Y'	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	viral load	Teyssou et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1	'E484K', 'N501Y'	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.K417N	c.G1251T	p.K417N			22813	S	S	MISSENSE	747	1472	742						0	T=747	747	T	G	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is -0.86 kcal/mol (i.e. destabilizing relative to wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 1.07x decrease in binding (KD) relative to D614G. Compare to increased binding in full Spike variant complements for major lineages containing this variant subset: 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	antibody epitope effects	McCallum et al. (2021)	https://doi.org/10.1101/2021.01.14.426475		"Massive reduction in S2L28 monoclonal antibody EC50 (i.e. ablated recognition), within antigenic supersite ""i"", but no effect on other mAbs within that supersite"	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		Ablates neutralization by N-terminal-domain-targeting mAbs 4-19. Impairs neutralization by N-terminal-domain-targeting mAbs 4A8 and 2-17.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.66x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset. Compare to decreased binding in full Spike variant complements for major lineages containing this variant subset: 0.96x (B.1.351 aka Beta), 0.77x (P.1 aka Gamma).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggetsing that this  mutation does not contributing to cell entry fitness.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.30x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.28x increase (B.1.351 aka Beta), and 1.14x decrease (P.1 aka Gamma). 1.47x decrease in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees. Compare to varied binding in full Spike variant complements for major lineages containing this variant subset: 1.17x increase (B.1.351 aka Beta), and 1.47x decrease (P.1 aka Gamma).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L18F	c.C52T	p.L18F			21614	S	S	MISSENSE	736	736	742						261	T=475	475	T	C	virion structure	Cai et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1	'D80A', 'L242del'	The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351.3=True, B.1.351.2=True, B.1.351=False	VOC		18-Dec-2020	
p.L241del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L242del', 'A243del'	22280	S	S		648	736	742						1	A=639	639	A	ACTTTACTTG						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	antibody epitope effects	Wang et al. (2021)	https://www.nature.com/articles/s41586-021-03398-2		B.1.351 pseudotyped virus model ablates neutralization by N-terminal-domain-directed mAbs 5-24, 4-8, 4A8, 2-17, and 4-19 (independent of S:p.R246I).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1		"Ablates binding of Spike N terminal domain targeting monoclonal antibody 4A8, by disruption of N5-loop/supersite loop, may work synergistically with  501Y.V2 (""South African"") lineage background variant R246I to disrupt paratope binding. [PG: del extent simplified to accomodate minor position realignments]"	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	convalescent plasma escape	McCarthy et al. (2021)	https://doi.org/10.1126/science.abf6950		Virus evolution data in 9 immunocomprised patients with long active COVID-19 infections was gathered, showing sequence deletion hotspots. This variant was present in 1 patient.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'A243del', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.351 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing mild decrease in infection rate amongst the cells, suggesting that this  deletion does not contributing to cell entry fitness.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy			'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'D215G', 'K417N', 'E484K', 'N501Y', 'D614G', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L242del	c.719_727delCTTTACTTG	p.L241_A243del	L241_A243del	'L241del', 'A243del'	22280	S	S		657	1472	742						1	A=648	648	A	ACTTTACTTG	virion structure	Cai et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.13.439709v1	'L18F', 'D80A'	The L18F and D80A of the B.1.351 lineage lead to reconfiguration of the N-terminal segment despite the disulfide between Cys16 and Cys136 that partly anchors the N-terminal peptide. The most consequential changes are probably from the triple residue deletion... which causes a shift of the nearby loop 144-155 and must also reconfigure the adjacent disorder loop (residues 246-260), both of which form part of the neutralizing epitopes...bringing large changes in the antigenic surface in this region.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.L5221F	c.C15661T	p.L5221F			15925	orf1ab	ORF1ab	MISSENSE	670	670	742			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	596	T=74	74	T	C						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.L6892L	c.G20676T	p.L6892L			20940	orf1ab	ORF1ab	SILENT	12	12	742			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	10	T=2	2	T	G						False	B.1.351.2	B.1.351.2=False	VOC		18-Dec-2020	
p.L71L	c.C211T	p.L71L			25603	ORF3a	ORF3a	SILENT	54	54	742						25	T=29	29	T	C						False	B.1.351.3	B.1.351.3=False	VOC		18-Dec-2020	
p.N2596S	c.A7787G	p.N2596S			8052	orf1ab	ORF1ab	MISSENSE	66	66	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	G=66	66	G	A						False	B.1.351.2, B.1.351.3	B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1		The N501Y mutation had the biggest effect on ACE2 affinity of any VOC mutation tested, increasing the affinity ~10 fold to KD ~7 nM, by increasing the k(on) ~1.8 fold and decreasing the k(off) by ~ 7 fold as measured by surface plasmon resonance. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'E484K'	In the case of VOC B.1.1.7+E484K, the addition of the E484K mutation to N501Y further increased the affinity, to ~15 fold higher than WT RBD (KD ~5 nM), by further increasing the k(on) as measured by surface plasmon resonance. Because the higher k(on) could result in mass transfer limiting binding, we confirmed that the kinetic measurement for this variant was not substantially affected by varying levels of immobilization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Barton et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.18.444646v1	'K417N', 'E484K'	The affinity of the B.1.351 RBD variants for ACE2 increased by 3.7 fold as measured by surface plasmon resonance relative to wild  type RBD by increasing the k(on) and decreasing the k(off) rate constants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		This combination showed ~3x increase binding to ACE2 vs wild type, about half that of the B.1.1.7 lineage, suggesting that the K417N mutation is slightly detrimental to ACE2 binding, probably as a result of disrupting the salt bridge formed with ACE2 residue D30	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Gamez et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.09.439154v1		The most frequent RBM mutation N501Y (165,519 instances) makes defective the atypical N-glycosylation  sequon NGV 501-503, becoming a key RBM position for the interaction with hACE2-binding hotspot 353.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	"Using flow cytometry and ACE2 ectodomains-Fc portion IgG complex, this variant showed a 2.52x increase in binding (KD) relative to D614G, mostly due to decreased in ""off-rate"" a.k.a. dissociation rate (Kdis). Compare to full Spike variant complements for major lineages containing this variant subset: 5.43x (B.1.1.7 aka Alpha), 3.56x (B.1.351 aka Beta), 4.24x (P.1 aka Gamma)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Laffeber et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432357v1		RBD containing the N501Y mutation results in 9-fold stronger binding to the hACE2 receptor than  wild type RBD. The E484K mutation does not significantly influence the affinity for the receptor,  while K417N attenuates affinity. As a result, RBD from B.1.351 containing all three mutations binds  3-fold stronger to hACE2 than wild type RBD but 3-fold weaker than N501Y.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.02.428884v1		Reported 10-fold increase in ACE2 binding vs wildtype (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		Studying the key covariants in lineage of concern 501Y.V2,  observed about 2-fold increase in ACE2 binding vs wildtype, but greatly decreased mAb binding, suggesting evolutionary optimum tension between  immune evasion and ACE2 binding affinity as the N501Y variant alone has 10x increase in affinity but no effect on tested mAb binding.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		~4-fold increase in binding affinity vs wild type.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Flow cytometry was used on recombinant VSV proteins and yeast surface display to assess the binding of a labeled soluble ACE2  protein to cells expressing B.1.351. We observed an increase (relative to D614G) in binding of soluble  ACE2 to B.1.351, and to a much gearter extent to B.1.1.7, which both carry the N501Y mutation (see Fig 3). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Microscale Thermopheresis, this variant binds ACE2 at nearly  two-fold greater affinity than the original SARS-COV-2 RBD (203.7 nM vs 402.5 nM).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Ramanathan et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.22.432359v1		Using Mircoscale Thermopheresis, the B.1.351 variant harboring three mutations, binds ACE2 at nearly  five-fold greater affinity than the original SARS-COV-2 RBD (Kd 87.6, vs 402.5 nM).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Santos and Passos (2021)	https://www.biorxiv.org/content/10.1101/2020.12.29.424708v1		In silico methods (PyMOL and PDBePISA) involving mutagenesis (N501Y mutation) and interface analysis focusing on the Spike  RDB-ACE2 interaction showed that the SARS-CoV-2 N501Y mutant (lineage B.1.1.7) establishes a more significant number of  interactions relating to the mutant residue Y501 (Spike RDB) with residues Y41 and K353 (ACE2). This finding shows that the  increased infectivity of SARS-CoV-2 lineage B.1.1.7 is associated with the interaction force between the Spike RBD Y501  mutant residue with the ACE2 receptor, which in this strain is increased.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Starr et al. (2020)	https://doi.org/10.1016/j.cell.2020.08.012		Experimentally, ACE2 binding affinity increased 0.24 fold	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		This single mutation causes major increase in binding affinity vs. wild type as measured by IC50 vs pseudotyped lentivirus,  but combined with the complete set of B.1.1.7   lineage variants no major change vs wild type affnity is observed. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported 4-fold increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Tian et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.14.431117v2		Reported slight increase in affinity compared to wild-type RBD on the cell surface (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1		The affinity of ACE2 for this mutation combination was twice as high as for wild type. Having in mind that the affinity of SARS-CoV-2 for ACE2 is only 4-fold higher compared to SARS-CoV-1, this factor of 2 is expected to be biologically significant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Zahradnik et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.06.425392		Among the first selected and fixed variants in an in vitro evolution experiment for ACE2 binding. Calculated disassociation constant for this variant is nearly four fold lower than wild type (Kd 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	ACE2 receptor binding affinity	Zhu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.11.426269v2		N501Y residue inserts into a cavity at the binding interface near Y41 of ACE2.  The additional interactions result in increased affinity of ACE2 for the N501Y mutant,  accounting for its increased infectivity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	CD8 plus T cell response	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Encouragingly, we find that the majority of T cell responses in recipients of two doses of the BNT162b2 vaccine are generated  by epitopes that are invariant between the [wildtype] and two of the current variants of concern (B.1.1.7 and B.1.351). In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals and recipients of a only a single dose of mRNA vaccine – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	T cell evasion	Reynolds et al. (2021)	https://science.sciencemag.org/content/early/2021/04/29/science.abh1282		Vaccinated, but not post-infection sera, show decreased average T cell response to an N501Y peptide. When we primed transgenic mice expressing human HLA-DRB1*0401 with the Wuhan Hu-1 peptide pool,  T cell responses to the B.1.1.7 variant peptide pool were significantly reduced (p 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 		Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58. Ablates Class 3 N-terminal domain targeting antibody COV2-2489, diminishes COV2-2676.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'E484K'	Ablates Class 1 receptor-binding-motif targeting antibodies COV2-2050, 1B07, COVOX-384, and S2H58.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Collier et al. (2021)	https://www.nature.com/articles/s41586-021-03412-7		Of 50 mAbs tested, major loss of neutralization observed for S2X128, S2D8, S2X192, S2D19, S2H14, S2H19.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Haynes et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.01.06.20248960v1		Wildtype elicits immune response, COVID-19 cohort epitope score > 99th percentile of the 497 pre-pandemic controls, mutant drops PIWAS epitope score from 3% to 1.2% (poorer immune recognition) Together with other B1.1.7 lineage mutational changes (Spike: Y144del, A570D, P681H, Nucleoprotein: D3L, S235F) resulted in only 2 or 579 individuals (0.3% of the population) having a dramatic reduction in PIWAS antigen scores, which reflects the peak epitope signal along the entire antigen.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'D614G'	Abolished neutralization by mAbs CQ026 and CQ038, greatly diminished neutralization by CQ012 and CQ046.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Klegerman et al. (2021)	https://doi.org/10.1101/2021.04.26.441517		Contrary to other reports on N501Y containing lineages (i.e. with additional mutations), N501Y alone may have an even greater affinity for a human monoclonal antibody specific for wild type. These results suggest that the individual N501Y mutation does not contribute to altered viral properties by itself, but may contribute to a collective conformational shift produced by multiple mutations.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Rees-Spear et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426849v1		Lowered the neutralization potency of mAb COVA1-12 to the limit of the assay. Decrease in potency was observed against the N501Y pseudotype for the cluster IX mAb COVA2-17.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Reduction in neutralization by mAbs COVA1-18 (~4x), COVA2-15 (~9x), S309 (~3x)	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G'	Anti-NTD CV1 mAb isolated from an early pandemic case was unable to neutralize either partial B.1.351 variant pseudovirus used (A701V or L242del). The neutralization potency of mAb CV30, which contacts K417 and N501 but not E484, was ~10-fold weaker toward both B.1.351 variants. The neutralization potency of anti-RBD mAb CV3-1 was 3-4-fold less potent against the B.1.351 variants, while anti-RBD mAb CV2-75 was modestly less effective.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Sun et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.22.436481v1	'K417N', 'E484K'	Complete loss of binding in ELISA by the variant against monoclonal antibodies ab8 and IgG1 ab1. Complete loss for the same antibodies was also observed against S1 pseudotyped and full Spike  protein trimers with both B.1.351 and P.1 lineage variants, with slight binding signal for P.1 against IgG1 at the highest concentration tested (1uM). Complete loss of neutralization by these two antibodies was also observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		4 antibodies tested were less potent against K417N by ten-fold or more, in both mAb classes 1 and 3	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	antibody epitope effects	Wibmer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.18.427166v1	'K417N', 'E484K'	"Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CA1 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody LyCoV016 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 1 (Spike 'up' conformation only, RBD targeting) monoclonal antibody CC12.1 on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody BD23 on 501Y.V2 (""South African"") lineage background  Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody C119 (also known as CB6 or JS016) on 501Y.V2 (""South African"") lineage background Ablates ELISA test binding for class 2 (Spike 'up' or 'down' conformation, RBD targeting) monoclonal antibody P2B-2F6 on 501Y.V2 (""South African"") lineage background"	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.65x increase in Spike binding (relative to D614G alone) by 5 plasma collected 8 months post-symptom-onset.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'K417N', 'E484K', 'D614G'	Average ~10-fold reduction in neutralization efficacy in convalescent sera of 16 health workers infected in Spring 2020.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Cele et al. (2021)	https://www.krisp.org.za/manuscripts/MEDRXIV-2021-250224v1-Sigal.pdf		The 501Y.V2 to first wave IC50 ratio ranged from 6 to 200-fold. Averaging across all 7 participant convalescent sera highlighted the dramatic decrease in sensitivity to neutralization of authentic 501Y.V2 variants. PG: I'm purposefully ignoring D614G and A701V as contributors	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'E484K'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against all samples. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w 	'K417N', 'E484K'	In 19 convalescent human sera ~1mo post infection had mild to moderate resistence against most samples	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'D614G'	Neutralizing antibody titers of 18 samples (90%) decreased against this B.1.351 pseudotyped virus below an ID50 threshold of 40 (sera  collected ~8mo post Jan 2020 first wave in China).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008		0.7x reduction in neutralization by key variant in several variants of concern in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K'	~7x reduction in neutralization by key B.1.351 lineage RBD variant combination in sera collected from cohort of 10 with severe  disease 21 to 63 days post-onset. Two of the cohort showed no neutralization against this variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Using a new rapid neutralization assay, based on reporter cells that become positive for GFP after overnight infection, sera from 58  convalescent individuals collected up to 9 months after symptoms had mean ~6x reduction in neutralizing titers, and 40% of the samples  lacked any activity against B.1.351. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		In 30 samples collected 111 to 260 days post onset of symptoms, the covalescent plasma can neutralize both  the reference USA-WA1/2020 strain and the mouse adapted strain that contains the N501Y spike mutation with similar efficiency.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Shen et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.27.428516v2		Neutralization activity of convalescent sera tested decreased ~2x with this B.1.1.7 pseudotyped virus.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Skelly et al. (2021)	https://doi.org/10.21203/rs.3.rs-226857/v1	'L18F', 'D80A', 'D215G', 'L242del', 'A243del', 'K417N', 'E484K', 'D614G', 'A701V'	In over 90% of two dose mRNA vaccinees, heterotypic neutralizing titres (NT50) against B.1.1.7 and B.1.351 remain comfortably  above the level associated with immune protection in recent vaccine trials. However, in over 50% of convalescent COVID-19  individuals (5/9) and recipients of a only a single dose of mRNA vaccine (10/11) – heterotypic neutralization dropped to negligible levels,  particularly against B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, one third (5/15) of sera neutralized this B.1.351 pseudotype and only three had ID50 titers above 100. Only two of the 15 sera achieved 80% neutralization.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G'	Using convalescent sera from 15 early pandemic patients (Seattle Flu Study), mean 220 days post symptom onset (IQR 125-269, and three asymptomatic cases) with 27% WHO disease severity scale 3, 7 of 15 neutralized this B.1.351 pseudotype that includes the L242del, and only one had titers above 100.  Only one of the 15 sera achieved 80% neutralization. [compare to 5 and 1 for pseudotype without the deletion]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Viruses containing the point mutations of B.1.1.7 showed that the single point mutations (Δ69-70 and N501Y) were neutralized as efficiently as D614G across 10 convalescent sera from April 2020 infectees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Tang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.19.436183v1		As measured by surface plasmon resonance, RBD with the N501Y mutation alone showed a mean 2.1x decrease in binding affinity for  six batches of hyperimmune immunoglobulin (hCoV-2IG) preparations generated from SARS-CoV-2 convalescent plasma.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Vogel et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.04.433887v1	'K417N', 'E484K'	Demonstrate (via competitive assays in human and mouse) immune escape from polyclonal antibodies induced by vaccination or infection, comparable to what was previously shown with monoclonal antibodies for N501Y and more importantly for E484K. Even though viral mutations may more strongly affect monoclonal antibodies than sera activity, the latter may also be reduced as confirmed here.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"27% of 44 early pandemic exposure convalescent plasma/sera lose all activity against a RBD triple mutant pseudovirus (RBD mutatants of the 501Y.V2 ""South African"" lineage), while only 23% retained high titres "	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	convalescent plasma escape	Wibmer et al. (2021)	https://doi.org/10.1101/2021.01.18.427166		"Nearly half (21 of 44, 48%) of early pandemic exposure convalescent plasma/sera failed to neutralize the 501Y.V2 (""South African"") lineage pseudovirus construct Only 3 of 44 convascent sera (those with the highest titer, which correlated direectly with initial infection severity) had high neutralization against this 501Y.V2  PG: note that lineage variant R246I was excluded from the text in reference to these sera assays, not sure if that was an oversight."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	environmental condition stability	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Relative to D614G, this mutation demonstrated significant increase in infectivity (i.e. heat stability) after incubation at 50C after 30 minutes or 1 hour	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	homoplasy	Flores-Alanis et al. (2021)	https://www.mdpi.com/2076-0817/10/2/184/htm		Variant within the six key residues in the receptor binding domain (RBD). Independently reported in UK, Australia  (same origin as UK), and South Africa (independent origin).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	humoral response durability	Betton et al. (2020)	https://doi.org/10.1093/cid/ciab308	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	In a prospective study of 107 hospitalized patients, decrease of IgG rates and serological assays becoming  negative did not imply loss of neutralizing capacity. Our results indicate a sustained humoral response against the  ancestral strain and the D614G, B.1.1.7 and P.1 variants for at least 6 months (last of two samples taken)  in patients previously hospitalized for COVID-19. A weaker protection was however observed for the B.1.351 variant.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	immunosuppression variant emergence	Choi et al. (2020)	https://www.nejm.org/doi/full/10.1056/NEJMc2031364		Appeared (day 128) and persisted in chronic (152 day) SARS-CoV-2 infection of immunocompromised patient with severe antiphospholipid syndrome	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	monoclonal antibody serial passage escape	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In vitro selection against class 1 (Spike 'up' conformation) monoclonal antibody C663, and to a lesser extent C613.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	outcome hazard ratio	Funk et al. (2021)	https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2021.26.16.2100348	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	On average across 7 European countries studied, using B.1.351 defining mutations: Significant shift to infection in those without pre-existing conditions (79.6% vs 89% for non-VOC cases). Significant increase in hospitalization rate (19.3% vs 7.5% for non-VOC cases). Significant increase in ICU rate (2.3% vs 0.6% for non-VOC cases). PG: seems to be different notations around the LAL deletion, using the minimal shared definition to catch as many as possible.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		COR-101 lost ~8x binding against this isolated mutation. Regdanvimab lost ~6x binding against this isolated mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1		Tixagevimab, Regdanvimab and COR-101 display reduced binding affinity to virus pseudotyped as RBD from B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'E484K'	Bamlanivimab (LY-CoV555) lost ~64x binding against this double mutation. COR-101 lost ~50x binding against this double mutation. Casirivimab lost ~250x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~32x binding against this double mutation. Tixagevimab lost ~10x binding against this double mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	pharmaceutical effectiveness	Engelhart et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.27.440939v1	'K417N'	COR-101 lost ~20x binding against this double mutation. Estesevimab lost ~16x binding against this double mutation. Regdanvimab lost ~6x binding against this double mutation. M396 lost ~10x binding against this double mutation.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	pharmaceutical effectiveness	Liu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.16.431305v1		This mutated version of RBD completely abolishes the binding to a therapeutic antibody, Bamlanivimab, in vitro.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	reinfection	Staub et al. (2021)	https://doi.org/10.2807/1560-7917.es.2021.26.18.2100423	'D80A', 'D215G', 'K417N', 'A701V', 'E484K'	4 health care workers in the 20's and 30's with no underlying conditions and seropositivity or confirmed 2020 SARS-CoV-2 infections were confirmed to have B.1.351 infection during a Februrary 2021 hospital outbreak in Luxembourg. Symptoms were mostly mild on first infection, and milder on second infection.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	reinfection	Yinda et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.05.442780v1	'D80A', 'D215G', 'K417N', 'A701V', 'E484K'	Hamsters re-infected with B.1.351 virus after seroversion from previous infection with a lineage A virus did not transmit  virus to naive sentinels via direct contact transmission, in contrast to the non-seroconverted animals. They had little  infectious virus and no pathology in the lungs. Initial infection with SARS-CoV-2 lineage A does not prevent heterologous reinfection with B.1.351, but prevents disease and onward transmission.  	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	symptom prevalence	Munster et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.07.443115v1	'D80A', 'D215G', 'K417N', 'A701V', 'E484K'	Inoculation with the B.1.351 isolate resulted in lower clinical scores in 6 rhesus macaques that correlated with lower virus  titers in the lungs, less severe histologic lung lesions and less viral antigen detected in the lungs. Our comparative  pathogenicity study suggests that ongoing circulation under diverse evolutionary pressure favors transmissibility and  immune evasion rather than an increase in intrinsic pathogenicity.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	Slight increase in Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, no change relative to D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	syncytium formation	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	~50% Vero cell-cell membrane fusion assay under infection with VSV pseudotyped virus relative to wild type, signficantly higher than D614G.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	tissue specific neutralization	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	The nasal mucosa of Pfizer vaccinees with time course collection was evaluated against VSV pseudotypes: while B.1.1.7 and D614G showed neutralization by nasal swab from only one different previously infected vacinee neutralizing at weeks 3 and 6, B.1.351 showed zero neutralization at either time point in any sample (and relatively impaired serum neutralization).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Hu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.22.427749v1	'K417N', 'E484K', 'D614G'	The entry efficiencies of Spike pseudotyped viruses bearing N501Y Variant 2 (B.1.351) mutant were about 3 to 4.4 times higher than that of the WT pseudovirus when viral input was normalized, suggesting that these spike variants promote the infectivity of SARS-CoV-2.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~9x, Vero ~8x, and Calu-3 ~8x. Compare to wild type at ~5x across cell types.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'D614G'	~4x more efficient S2 domain cleavage compared to wild type, no change relative to D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	More efficient infectivity (24h) compared to wild type, in Caco-2 cells ~11x, Vero ~10x, and Calu-3 ~11x. Compare to wild type at ~5x across cell types.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kim et al. (2021)	https://dx.doi.org/10.3390%2Fv13040633	'E484K', 'D614G'	~6x more efficient S2 domain cleavage compared to wild type, compared to 4x by D614G alone in Caco-2 cells, mid-range of three cell line tested (Vero and Calu-3). [N501Y+D614G does not show an increase in cleavage, therefore a synergistic effect of the trio is implied]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	736	1472	742						0	T=736	736	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	~12x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (~additive effects of 501 and 484).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'K417N', 'D614G'	~13x more infective as D614G alone in HEK293T-ACE2 cells 48h post-transduction.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	~9x more infectivity than D614G alone in HEK293T-ACE2 cells 48h post-transduction (no synergy as level approx. that of N501Y alone).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Motozono et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.02.438288v1		Decreased stability of RBD expression in yeast, suggesting decreased Spike protein stability.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	trafficking	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.05.430003v1		Lentiviral pseudotyped with this individual mutation from B.1.1.7 was tested on ACE2.293T cells. Luciferase activity was measured two days postinfection,  showing slightly increased infection rate amongst the cells.  [in what is essentially a replicate experiment in the same paper, because  each B.1.351 lineage variant was independetly evaluated and N501 is in both lineages,  a significant decrease was observed, therefore the error bars described in this paper should be interpreted carefully]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	transmissibility	Pearson et al. (2021)	https://cmmid.github.io/topics/covid19/reports/sa-novel-variant/2021_01_11_Transmissibility_and_severity_of_501Y_V2_in_SA.pdf	'K417N', 'E484K', 'D614G'	Assuming complete cross-protection, we estimate 501Y.V2/B.1.351 was 1.50 (95% CrI: 1.20-2.13) times as transmissible than previously circulating variants. Assuming instead that 501Y.V2 is identically transmissible, the new variant evades 21% (95% CrI: 11-36%) of previously acquired immunity. Reality may lie between these extremes, with an intermediate increase in transmissibility and mildly imperfect cross-protection from past exposure. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	transmissibility	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.05.12.21257130v1	'K417N', 'E484K', 'D614G'	36,590 variant-specific RT-PCR tests were performed on samples collected between April 12 and May 7, 2021  in France to compare variant spread. Compared to January to March 2021, B.1.351 variant had a significant  transmission advantage over B.1.1.7 in some regions (15.1 to 16.1% in Île-de-France and 16.1 to 18.8% in Hauts-de-France). This shift in transmission advantage is consistent with the immune evasion abilities of B.1.351 and the high levels of immunization in these regions.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy			'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	The Janssen single dose vaccine showed 72% efficacy at preventing moderate and severe disease, which was  reduced to 57% in South Africa, where 92.6% of infections are estimated to have been B.1.351. 100% reduction in  hospitalization risk remains across variants after 28 days post-vaccination.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Abe et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.08.06.21261721v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G'	In an Ontario long term care facility, cumulatively, weaker BNT162b2 vaccine stimulation, age/comorbidities, produced a ∼130-fold reduction  in apparent neutralization titers in mean 88yo LTCH residents against Beta (B.1.351), relative to staff vaccinees against D614G wild type.  37.9% of 116 two-dose-mRNA-vaccinated residents had undetectable neutralizing antibodies to B.1.351. mRNA-1273 vaccinee sera displayed ~2 better neutralization than BNT162b2. [common defining B.1.351 mutations noted, as the manuscript does not provide details]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Alenquer et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.22.441007v1	'D80A', 'D215G', 'K417N', 'E484K', 'A701V'	Using B.1.351 defining mutations for Spike, observed 4x average decrease in neutralization efficiency  (but still relevant titres) for sera from 10 BNT162b2 vaccinees 12 days after second dose, but only one  relevant titre 12 days after first dose. Compares unfavorably to wild type or B.1.1.7 titres.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1		Observed 1.3-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.1.7 key variant lentivirus. Compare to 2.6-fold reduction against cultured B.1.1.7 virus.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'K417N', 'E484K'	Observed 1.4-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose)  against pseudotype B.1.351 key variants lentivirus. Compare to 8.8-fold reduction against cultured B.1.351 virus.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Bates et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.04.21254881v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	"Observed 8.8-fold reduction in neutralization efficiency of Pfizer vaccinee sera (collected 14 days after second dose) against cultured B.1.351 sample. Contrast this with 1.4-fold reduction for just the pseudovirus combination of ""key"" B.1.351 mutations K417N+E484K+N501Y. WA1 and B.1.351 FRNT50 titers correlated weakly at the individual level, with some individual’s serum potently neutralizing WA1 while having FRNT50 for B.1.351 below the assay limit of detection (1:20)."	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Chen et al. (2021)	https://www.nature.com/articles/s41591-021-01294-w	'E484K'	The neutralizing activity of vaccine was slightly to significantly lower against this variant combination in sera from all 24 patients with  the BNT162b2 mRNA vaccine. (Fig. 4) [In stark contrast to this combination plus K417N, which had no effect (P<0.0001 vs. P	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v3 reduced 8.4x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Choi et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.06.28.449914v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Neutralization efficiency (ID50) against B.1.1.351-v2 reduced 7.3x relative to D614G wildtype using pseudotyped VSV assay on 8 Moderna vaccinee sera one week post-booster.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Edara et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.02.21250799v1		1.2x drop in neutralization using sera collected from 14 healthy adult participants that received two injections of the mRNA-1273 (Moderna) vaccine  at a dose of 100 µg (18-55 years: day 1 and day 14 post-2nd dose) against a recombinant single variant virus (modified replicating WA-1 cDNA clone)  relative to contemporary circulating D614G variant (USA/GA-EHC-083E/2020) using a live-virus Focus Reduction Neutralization Test (FRNT) assay. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Gallagher et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.03.442455v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	ELISpot assays show T cell neutralization reduced by 29.8% in this B.1.351 pseudotype relative to wild type in 18-20 pooled patient samples post second mRNA vaccine dose, with no significant difference between Pfizer and Moderna cohorts. Reduction was stronger in the S1 subunit than S2 (separate peptide pools were used).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Pseudotyped B.1.351 v1 virus has reduced neutralization activity vs wild type: 34.5x (30 sera Pfizer median 9 days post 2nd dose)  and 27.7x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Garcia-Beltran et al. (2021)	https://doi.org/10.1016/j.cell.2021.03.013	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Pseudotyped B.1.351 v2 virus has reduced neutralization activity vs wild type: 41.2x (30 sera Pfizer median 9 days post 2nd dose)  and 20.8x (35 sera Moderna median 18 days post 2nd dose). This was significant by ANOVA. Notably, 36.7% (11/30) recipients of two-dose Pfizer and 42.9% (15/35) recipients of two-dose Moderna vaccines did not have  detectable neutralization of at least one of the B.1.351 variants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Ikegame et al. (2021)	https://dx.doi.org/10.21203%2Frs.3.rs-400230%2Fv1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	B.1.351 pseudotyped VSV was tested for neutralization in a clonal HEK-293T ACE2 TMPRSS2 cell line optimized for highly efficient  S-mediated infection. Only 1 out of 12 serum samples from a cohort of Argentinian recipients of the Gamaleya Sputnik V Ad26 / Ad5 vaccine  showed effective neutralization (IC90) at full serum strength (average realtive decrease was 6.1x vs wild type).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Jacobson et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.04.14.21255431v2		The presence of this variant in 189 post-mRNA-vaccination COVID-19 cases was proportionally in line with lineage prevalence in Northen California during the study period, suggesting no effect of these variants on immune escape.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'D614G'	This variant showed no change in Pfizer sera (one or two dose) neutralization efficiency vs D614G (using lentivirus pseudotype).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'E484K', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'D614G'	This variant showed >5x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K'	In post-vaccination sera from individuals who received one (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Kuzmina et al. (2021)	https://dx.doi.org/10.1016%2Fj.chom.2021.03.008	'K417N', 'E484K', 'D614G'	This variant of key B.1.351 lineage mutations showed ~10x decrease in Pfizer sera (3 weeks post-first dose: n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Liu et al. (2021)	https://www.nejm.org/doi/full/10.1056/NEJMc2102017	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Vaccine plasma neutralization of B.1.351-spike virus was nominally robust but lower (~3x) than other variants of concern.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.02.10.21251247v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	A two-dose regimen of (AstraZeneca) ChAdOx1-nCoV19 did not show protection against mild-moderate Covid-19 due to B.1.351 variant, however,  vaccine efficacy against severe Covid-19 is undetermined.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'K417N', 'E484K', 'D614G'	In a multicenter, double-blind, randomized, controlled trial to assess the safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) with enrollment June 24 and November 9, 2020 from ~2000 HIV-negative 18-64 year olds (1:1 placebo to treatment), incidence of serious  adverse events 14 or more days post- 2nd dose was balanced between the vaccine and placebo groups. A two-dose regimen of the ChAdOx1  nCoV-19 vaccine did not show protection against mild-to-moderate Covid-19 due to the B.1.351 variant. Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed 3.5x reduction in neutralization (ID50) for B.1.351 RBD pseudotype HIB-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a similar 3.2x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Madhi et al. (2021)	https://doi.org/10.1056/NEJMoa2102214	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Relative to B.1.1.117, PRNT50 line virus neutralizating antibody activity assay of B.1.351 showed ~11x reduction in 13 vacinees's sera  collected through 41 days after vaccination. Neutralization by a placebo control group of 6 naturally infected patients showed a smaller ~8x drop (starting from a ~50% higher PRNT50 value than vacinees for B.1.1.117 neutralization). Serum samples obtained from 13 ChAdOx1 nCoV-19 vaccine recipients without SARS-CoV-2 infection through 41 days after vaccination  showed ~4x reduction in neutralization (ID50) for full B.1.351 pseudotype HIV-1 virus compared to D614G alone. This  RBD variant combination's neutralization by a placebo control  group of 6 naturally infected patients showed a slightly higher 4.6x drop (though with D614G starting at a 1.7x higher titre than vaccinee sera).	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Novavax (2021)	https://www.novavax.com/sites/default/files/2021-02/20210202-NYAS-Novavax-Final.pdf	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	The Novavax vaccine, which achieved 95.6% efficacy against previous SARS-CoV-2 strains, had reduced efficacy of 60% in South Africa,  where 92.6% of infections are estimated to have been B.1.351.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Pegu et al (2021)	https://www.biorxiv.org/content/10.1101/2021.05.13.444010v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G'	Detectable antibodies against B.1.351 at various time points using pseudotyped lentivirus neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 71%, Day 209 54%. Detectable antibodies against B.1.351 at various time points using live virus FRNT neutralization in Moderna vaccinee cohort: Day 29 8%, Day 43 100%, Day 119 79%, Day 209 58%. Detectable antibodies against B.1.351 at various time points using ACE2 blocking assay in Moderna vaccinee cohort: Day 29 63%, Day 43 100%, Day 119 71%, Day 209 79%. Decreased neutralization on some assays was seen especially in those vaccinees tested that were 71+.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Planas et al. (2021)	https://www.nature.com/articles/s41591-021-01318-5	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	The sera of 16 individuals with time course collection was evaluated against VSV pseudotypes: while BD614G and B.1.1.7 were  neutralized earlier, the anti-B.1.351 response was negative up to week 3, and became detectable at week 4 (1 week after booster dose), at a level lower  than the two other viruses (~10x vs D614G) through week 6, the last timepoint measured. Three vaccinees never showed detectable neutralization to B.1.351 even after second dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Rathnasinghe et al. (2021)	https://dx.doi.org/10.1101%2F2021.01.19.21249592		Human sera from 6 two-dose Pfizer vaccinated individuals (47-68 days post 1st-dose) can neutralize both the reference  USA-WA1/2020 strain and the mouse adapted SARS-CoV-2 strain that contains the N501Y spike mutation with similar efficiency.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Shinde et al. (2021)	https://doi.org/10.1056/nejmoa2103055	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	In a randomized phase 2a-b control trial of the Novavax (NVX-CoV2373) vaccine in South Africa, where B.1.351 virus dominates, efficacy was 60.1% (95% CI, 19.9 to 80.1) in HIV-negative and initially SARS-CoV-2 seronegative participants using the  primary endpoint of laboratory-confirmed symptomatic Covid-19 at 7 days or more after the second dose among participants. 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'K417N', 'E484K', 'A701V', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~3-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~10 fold with L242del] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were signficiant, but >100x weaker than in previously infected  patients after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Stamatatos et al. (2021)	https://doi.org/10.1126/science.abg9175	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G'	In sera collected from 15 early pandemic patients (Seattle Flu Study), mean 16 days post first dose with either Pfizer/BioNTech or Moderna vaccines,  the median ID50 titers were ~10-fold lower against this B.1.351 pseudotyped virus relative to wild type. A single asymptomatic patient, who had no detectable RBD-specific IgG memory before vaccination, also did not elicit nAbs against the B.1.351 variant. [compare to ~3 fold without the deletion] ID50 titres in non-infected mRNA vaccines more than two weeks post-booster were significant, but ~500x weaker than in previously infected patients  after first dose.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Tada et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.05.14.444076v1	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G'	Pseudotyped viruses for B.1.351 was 3.4-fold resistant to neutralization by 6 BNT162b2 vaccine sera 28 days post-booster compared to wild type. Neutralization by 3 Moderna vaccine sera 28 days post-booster was 2.2-fold resistant. [Exact list of B.1.351 mutations used in these assays was not included in the preprint]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Tarke et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.02.27.433180v1	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	PBMCs of Pfizer/BioNTech BNT162b2 (n	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Voysey et al. (2021)	https://doi.org/10.1016/S0140-6736(20	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	[Contrary to how this paper has been cited, Voysey et al. do NOT show evidence of decreased effectiveness of ChAdOx1 (AstraZeneca) against  the South African B.1.351 lineage. Insufficient numbers reaching the primary study endpoint were available in that arm of the vaccine study to report any statistics from the South African participants. Additionally, the study period of the paper ended in November 2020, while the earliest reported case of this lineage is October (covariants.org), only becoming dominant by mid-November.]	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2		In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a modest decrease in neutralization by vaccine plasma was observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Wang et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.15.426911v2	'K417N', 'E484K'	In a cohort of 20 patients 8+ weeks after second vaccine dose of Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) vaccines,  a significant (0.5 to 20-fold, but average ~2x) decrease in neutralization by vaccine plasma was observed.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Woldemeskel et al. (2021)	https://doi.org/10.1172/jci149335	'L18F', 'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	No significant difference in T-cell response to B.1.351 was observed (vs. ancestral) in blood drawn from 28 participants received the Pfizer-BioNTech vaccine  and 2 received the Moderna vaccine.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Wu et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.01.25.427948v1	'K417N', 'E484K'	In Moderna vaccinee sera, 2.7x reduction in neutralization, and 6.4 for the full B.1.351 Spike mutation complement, but despite the observed decreases,  titers in human vaccinee sera against the B.1.351 variant remained at clinically significant level of ~1/300.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Xie et al. (2021)	https://www.nature.com/articles/s41591-021-01270-4	'E484K'	In 20 sera from BNT162b2 mRNA vaccine inoculated participants, 6 displayed mild (2x) reductions in neutralization. This variant combination showed the highest reduction, but the magnitude of the differences was small  compared to the >4x differences in HA-inhibition titers that have been used to signal potential need for a strain change in influenza vaccines.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccine neutralization efficacy	Zhou et al. (2021)	https://doi.org/10.1016/j.cell.2021.02.037	'D80A', 'D215G', 'L242del', 'K417N', 'E484K', 'D614G', 'A701V'	Sera from healthcare workers (n 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	vaccinee plasma binding	Gong et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.08.04.455140v1	'D614G'	1.17x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in previously non-seroconverted subjects.  1.09x increase in Spike binding (relative to D614G alone) by 5 plasma collected 3 weeks after one dose of Pfizer/BioNtech BNT162b2 vaccine in post-infection vaccinees.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	viral load	Roquebert et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.19.21253971v2	'K417N', 'E484K'	B.1.351 and P.1 samples showed average Ct cycle threshold of 22.2 vs 23 for wildtype (i.e. ~60% higher viral load) comparing 3360 and 22535 samples respectively.	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	viral load	Teyssou et al. (2021)	https://www.medrxiv.org/content/10.1101/2021.03.21.21253498v1	'K417N', 'E484K'	The 62 B.1.351 (a.k.a. N501Y.V2) variant cases in three Paris hospital labs had a ~2-fold viral load increase  (~1 Ct drop in both N and ORF1ab probes) compared to 332 ancestral lineage cases from the same time frame (2020-12-20 to 2021-02-26). 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N501Y	c.A1501T	p.N501Y			23063	S	S	MISSENSE	724	736	742						0	T=724	724	T	A	virion structure	Spratt et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.03.24.436850v1		Estimated free energy change (ddG) for this variant is 0.69 kcal/mol (i.e. stabilizing relative to wild type) 	False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.N7084N	c.C21252T	p.N7084N			21516	orf1ab	ORF1ab	SILENT	54	54	742			2'-O-ribose methyltransferase	nsp16_OMT, 2'-o-MT, produced by pp1ab only	YP_009725311.1	43	T=11	11	T	C						False	B.1.351.3	B.1.351.3=False	VOC		18-Dec-2020	
p.P2046L	c.C6137T	p.P2046L			6402	orf1ab	ORF1ab	MISSENSE	52	54	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	T=52	52	T	C						False	B.1.351.3	B.1.351.3=True	VOC		18-Dec-2020	
p.P4715H	c.C14144A	p.P4715H			14408	orf1ab	ORF1ab	MISSENSE	670	670	742			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	A=382, T=288	382,288	A,T	C						False	B.1.351	B.1.351=True	VOC		18-Dec-2020	
p.P4715L	c.C14144T	p.P4715L			14408	orf1ab	ORF1ab	MISSENSE	66	120	742			RNA-dependent RNA polymerase	nsp12, NiRAN and RdRp, produced by pp1ab only	YP_009725307.1	0	T=66	66	T	C						False	B.1.351.2, B.1.351.3	B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.P6714S	c.C20140T	p.P6714S			20404	orf1ab	ORF1ab	MISSENSE	54	54	742			endoRNAse	nsp15-A1 and nsp15B-NendoU, produced by pp1ab only	YP_009725310.1	36	T=18	18	T	C						False	B.1.351.3	B.1.351.3=False	VOC		18-Dec-2020	
p.P71L	c.C212T	p.P71L			26456	E	E	MISSENSE	736	736	742						0	T=736	736	T	C						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.Q57H	c.G171T	p.Q57H			25563	ORF3a	ORF3a	MISSENSE	736	736	742						0	T=736	736	T	G						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.S1612L	c.C4835T	p.S1612L			5100	orf1ab	ORF1ab	MISSENSE	670	670	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	554	T=116	116	T	C						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.S171L	c.C512T	p.S171L			25904	ORF3a	ORF3a	MISSENSE	726	736	742						0	T=726	726	T	C						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.S3675del	c.11023_11031delTCTGGTTTT	p.S3675_F3677del	S3675_F3677del	'3676del', 'F3677del'	11287	orf1ab	ORF1ab		736	736	742			nsp6	nsp6_TM, putative transmembrane domain, produced by both pp1a and pp1ab	YP_009725302.1	0	G=736	736	G	GTCTGGTTTT						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.S74S	c.C222T	p.S74S			25614	ORF3a	ORF3a	SILENT	670	670	742						452	T=218	218	T	C						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.T205I	c.C614T	p.T205I			28887	N	N	MISSENSE	736	736	742						0	T=736	736	T	C						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.T265I	c.C794T	p.T265I			1059	orf1ab	ORF1ab	MISSENSE	736	736	742			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	0	T=736	736	T	C						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.T362I	c.C1085T	p.T362I			29358	N	N	MISSENSE	669	670	742						563	T=106	106	T	C	T cell evasion	de Silva et al. (2021)	https://www.biorxiv.org/content/10.1101/2021.04.08.438904v1		"Variant causes complete loss of T cell line responsiveness to A*03:01/A*11:01-restricted CD8+ N epitope  KTFPPTEPK 361-369(2,8,10,20), which otherwise is ""consistently dominant and of high magnitude""."	False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.T734T	c.A2202T	p.T734T			23764	S	S	SILENT	670	670	742						596	T=74	74	T	A						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.T809T	c.A2427T	p.T809T			2692	orf1ab	ORF1ab	SILENT	736	736	742			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	119	T=617	617	T	A						False	B.1.351.2, B.1.351, B.1.351.3	B.1.351=True, B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.V2453V	c.T7359C	p.V2453V			7624	orf1ab	ORF1ab	SILENT	54	54	742			nsp3	former nsp1, conserved domains are: N-terminal acidic (Ac), predicted phosphoesterase, papain-like proteinase, Y-domain, transmembrane domain 1 (TM1), adenosine diphosphate-ribose 1''-phosphatase (ADRP), produced by both pp1a and pp1ab	YP_009725299.1	0	C=54	54	C	T						False	B.1.351.3	B.1.351.3=True	VOC		18-Dec-2020	
p.V3377V	c.G10131T	p.V3377V			10396	orf1ab	ORF1ab	SILENT	66	66	742			3C-like proteinase	nsp5A_3CLpro and nsp5B_3CLpro, main proteinase (Mpro), mediates cleavages downstream of nsp4. 3D structure of the SARSr-CoV homolog has been determined (Yang et al., 2003), produced by both pp1a and pp1ab	YP_009725301.1	0	T=66	66	T	G						False	B.1.351.2, B.1.351.3	B.1.351.3=True, B.1.351.2=True	VOC		18-Dec-2020	
p.V751V	c.G2253A	p.V751V			2518	orf1ab	ORF1ab	SILENT	54	54	742			nsp2	produced by both pp1a and pp1ab	YP_009725298.1	48	A=6	6	A	G						False	B.1.351.3	B.1.351.3=False	VOC		18-Dec-2020	
p.W131L	c.G392T	p.W131L			25784	ORF3a	ORF3a	MISSENSE	664	670	742						286	T=378	378	T	G						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
p.Y123Y	c.T369C	p.Y123Y			28642	N	N	SILENT	670	670	742						598	C=72	72	C	T						False	B.1.351	B.1.351=False	VOC		18-Dec-2020	
